Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 6,047 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 6,047 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $591.00, for a total value of $3,573,777.00. Following the completion of the transaction, the chief executive officer directly owned 893,368 shares of the company’s stock, valued at approximately $527,980,488. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Medpace Stock Up 0.8%

MEDP stock traded up $4.42 during midday trading on Tuesday, hitting $590.18. The company’s stock had a trading volume of 219,107 shares, compared to its average volume of 415,017. The stock’s 50-day moving average price is $541.26 and its 200 day moving average price is $426.46. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $625.00. The stock has a market cap of $16.62 billion, a price-to-earnings ratio of 41.27, a PEG ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business’s revenue was up 23.7% compared to the same quarter last year. During the same period last year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on MEDP shares. TD Cowen raised their price target on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Cowen reissued a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Deutsche Bank Aktiengesellschaft increased their price target on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. William Blair reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, July 23rd. Finally, Robert W. Baird set a $613.00 target price on shares of Medpace in a research note on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $487.18.

Institutional Investors Weigh In On Medpace

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Fifth Third Wealth Advisors LLC lifted its position in Medpace by 2.6% during the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the last quarter. BOKF NA raised its position in shares of Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after buying an additional 20 shares in the last quarter. HighPoint Advisor Group LLC raised its position in shares of Medpace by 2.8% during the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock valued at $416,000 after buying an additional 22 shares in the last quarter. Portside Wealth Group LLC grew its position in Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock worth $342,000 after acquiring an additional 27 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after acquiring an additional 27 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.